GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » EV-to-FCF

XOMA Royalty (STU:X0M1) EV-to-FCF : -34.71 (As of Sep. 24, 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, XOMA Royalty's Enterprise Value is €263.85 Mil. XOMA Royalty's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-7.60 Mil. Therefore, XOMA Royalty's EV-to-FCF for today is -34.71.

The historical rank and industry rank for XOMA Royalty's EV-to-FCF or its related term are showing as below:

STU:X0M1' s EV-to-FCF Range Over the Past 10 Years
Min: -199.93   Med: -6.6   Max: 105.25
Current: -35.63

During the past 13 years, the highest EV-to-FCF of XOMA Royalty was 105.25. The lowest was -199.93. And the median was -6.60.

STU:X0M1's EV-to-FCF is ranked worse than
100% of 395 companies
in the Biotechnology industry
Industry Median: 8.23 vs STU:X0M1: -35.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-24), XOMA Royalty's stock price is €25.00. XOMA Royalty's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.288. Therefore, XOMA Royalty's PE Ratio for today is At Loss.


XOMA Royalty EV-to-FCF Historical Data

The historical data trend for XOMA Royalty's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty EV-to-FCF Chart

XOMA Royalty Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.39 48.70 -37.18 -5.43 -10.11

XOMA Royalty Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.40 -7.06 -10.11 -14.52 -30.69

Competitive Comparison of XOMA Royalty's EV-to-FCF

For the Biotechnology subindustry, XOMA Royalty's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's EV-to-FCF falls into.



XOMA Royalty EV-to-FCF Calculation

XOMA Royalty's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=263.846/-7.602
=-34.71

XOMA Royalty's current Enterprise Value is €263.85 Mil.
XOMA Royalty's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (STU:X0M1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

XOMA Royalty's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.00/-2.288
=At Loss

XOMA Royalty's share price for today is €25.00.
XOMA Royalty's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.288.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


XOMA Royalty EV-to-FCF Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines